Resmed Inc
ASX:RMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (7), the stock would be worth AU$36.14 (22% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.7 | AU$29.69 |
0%
|
| 3-Year Average | 7 | AU$36.14 |
+22%
|
| 5-Year Average | 7.8 | AU$40.54 |
+37%
|
| Industry Average | 1.7 | AU$9.06 |
-69%
|
| Country Average | 2.4 | AU$12.65 |
-57%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
AU$36.7B
|
/ |
Jan 2026
$5.4B
|
= |
|
|
AU$36.7B
|
/ |
Jun 2026
$5.7B
|
= |
|
|
AU$36.7B
|
/ |
Jun 2027
$6.1B
|
= |
|
|
AU$36.7B
|
/ |
Jun 2028
$6.5B
|
= |
|
|
AU$36.7B
|
/ |
Jun 2029
$7B
|
= |
|
|
AU$36.7B
|
/ |
Jun 2030
$7.7B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Resmed Inc
ASX:RMD
|
30.9B AUD | 5.7 | 20.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 16 | 56.4 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 3.5 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 4.8 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 2.9 | 22.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 4.1 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 7.5 | 43 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 10.3 | 41.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 1.7 | 18.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 1.9 | 23.5 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
27.1B USD | 1.3 | 13 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Resmed Inc
Glance View
ResMed Inc. has built its legacy on a profound, technological commitment to improving the lives of millions worldwide who suffer from sleep-related breathing disorders. Emerging as a beacon in the field of medical device innovation, the company is renowned for its focus on designing and manufacturing equipment to treat sleep apnea, a condition where breathing repeatedly stops and starts during sleep. Their product line, which includes continuous positive airway pressure (CPAP) devices, ventilators, and masks, caters to hospitals, home healthcare settings, and individuals. By addressing this critical health issue, ResMed doesn't just deliver therapeutic equipment; it offers a lifeline to those battling sleep health challenges, ensuring that restful nights translate into healthier days. The company's revenue model pivots around an integrated approach combining hardware sales, software solutions, and cloud-connected offerings. Through its software, ResMed analyzes vast pools of patient data, enabling healthcare providers to tailor and improve therapeutic protocols, thus driving the efficacy of treatment plans. The increasing turn towards digital health technologies has also opened new avenues, with the company's cloud platforms and analytics delivering value-added insights to care providers. This convergence of medical equipment and digital technology provides ResMed not just a steady growth trajectory, but also positions it at the forefront of a healthcare evolution, turning data-driven intelligence into actionable health solutions.
